Ultomiris subcutaneous — Medica
Atypical hemolytic uremic syndrome (aHUS)
Initial criteria
- Patient age ≥ 18 years
 - Patient does not have Shiga toxin E. coli-related hemolytic uremic syndrome
 - Patient has received or will receive Ultomiris intravenous infusion loading dose prior to initiation of Ultomiris subcutaneous
 - Medication is prescribed by or in consultation with a nephrologist
 
Approval duration
1 year